Pre-clinical studies have shown that TRAIL and agonistic antibodies directed to TRAIL receptors can induce apoptosis in cancer cell lines and inhibit tumour growth in xenograft models (Pukac et al, 2005; Ashkenazi, 2008; Humphreys and Halpern, 2008; Johnstone et al, 2008). Here, TNFSF10 is linked to neoplasm.